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▶ Pathological hallmarks :  beta-amyloid + 
hyperphosphorylated tau protein + synapses loss
▶ Complex relationship and progressive pre-clinical temporal 
evolution
▶ Study of the earliest stages of the pathology
▶ Synaptic brain dysfunction : early marker ? 
▶ Synaptic decrease in the inferior temporal cortex in MCI
1. Scientific context : Alzheimer pathology
▶ Individual’s self-perception of the worsening of one’s 
cognitive capacities despite normal objective performance 
level in standard cognitive testing 
▶ Memory-specific complaints 
▶ Heterogeneous population by definition comprising non-AD 
pathology
▶ Identification of sub-population with increased risk of MCI -
AD conversion
1. Scientific context : Subjective cognitive 
decline (SCD)




▶ “Biomarkers” : APOE4, CSF, PET, MRI, …
▶ (Para-)hippocampal regions  : GM atrophy, hypometabolism, 
beta-amyloid / tau deposits
1. Scientific context : SCD ”plus”
▶ Glycoprotein in the membranes of synaptic vesicles
▶ Ubiquitous. Biomarker of synaptic density
▶ Physiological role is unclear
▶ Therapeutic target of antiepileptic drug (levetiracetam)
▶ Reduced in hippocampus in dementia (post-mortem)
1. Scientific context : Synaptic vesicle protein 2A
▶ Specific biding to SV2A sites in rodents 
▶ Acceptable dosimetry for human studies
▶ Consistent human brain distribution
▶ Moderate AD : decreased in MTL, precuneus and lateral 
associative cortices
▶ MCI – AD : decreased in medial and inferior temporal cortex
1. Scientific context : [18F]UCB-H

1. Scientific context
2. Questions, hypothesis, and experimental design 
3. Data acquisition & subjects
4. Data processing & inference




▶ To quantify SCD (measured with Ecog) and awareness about SCD 
(with questionnaires to participants and relatives) and their 
relationships with biomarkers for preclinical AD
▶ To study MR imaging biomarkers of cognitive fitness related to 
preclinical AD stages (synaptic loss and amyloid brain 
deposition). 
▶ To explore the relationship between short-term (18 months) 
cognitive evolution and AD-MCI conversion and neuroimaging 
markers
2.1. : Primary objectives
▶ Hypothesis 1a : SCD severity and worries (as dependant variable) will be better 
explained by loss of hippocampal synaptic density (SV2A-PET) than brain 
amyloid deposit (FLUT-PET). 
- Hypothesis 1b : SCD severity and worries will also be related to anxiety, age, sex, education and 
ApoE as covariates
▶ Hypothesis 2 : Hippocampal synaptic density (SV2A-PET) will be related to 
transentorhinal cortex atrophy (MRI), cortical amyloid deposit (FLUT-PET) and 
to data from MPM of the basal forebrain
▶ Hypothesis 3 : Awareness for SCD (and anosognosia) will be related to loss of 
hippocampal synaptic density (SV2A-PET), with possible higher default mode 
network connectivity (fMRI).
▶ Hypothesis 4 : 18-month longitudinal evolution of memory performance, SCD 
severity and awareness of memory functioning will be best related to decrease 
in hippocampal and posterior cingulate synaptic density.
2.2. : Hypotheses
▶ 18 month longitudinal observational multimodal study
▶ Cohort of “normal” individual aged 50 – 70 
▶ Evaluation of risk factors of AD :
- Neuropsychological evaluation
- Affective status
- Amyloid – PET (Flutemetamol)
- SV2A-PET (UCB-H)
- Quantitative structure MRI
- ApoE polymorphism
▶ T1 = Month 1  (Visit 1 + Visit 2)
▶ T2 = Month 18 (Visit 1 + Visit 2)
2.3. : Experimental design (1/2)
▶ Visit 1 (2h30) : 
- General and medical evaluation (1h)
- Amyloid-PET (45min)
- MRI (45min)
▶ Visit 2 (3h) : 
- Neuropsychological testing (1h15)
- SV2A – PET (1h50)
- Saliva for ApoE (5min)
2.3. : Experimental design (2/2)
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▶ N  SCD = 60  +  N Control group = 20
▶ Inclusion criteria = General SCD definition ; Age 50 - 90
- Subjective experience of cognitive difficulties (memory +/- other domains)
- Neuropsychological measures within normal range
- Complaints > 6 month
▶ Exclusion criteria
- Major psychiatric disorder
- Comorbidities affecting cognition (cancer, stroke, …)
- Chronic alcohol consumption
- Medications affecting cognitive (including long-acting bzd)
- Objective deficit in any neuropsychological or functional evaluation (CDR, 
Lawton, MMSE, …)
- Exclusion criteria for MRI
3. Data acquisition & subjects
▶ Wednesday or Thursday
▶ Team : 1 MD + 1 neuropsychologist
▶ Medical questionnaire and examination
3. Data acquisition : Clinical  evaluation
Participant Informant
Beck depression  inventory
STAI
Modified Hachinski ischaemic scale






▶ Wednesday or Thursday
▶ Team : 1 MD + 1 Nurse
▶ Flutemetamol = Vizamyl®. Synthesized on site by Nucleis S.A. and the 
radiopharmacist will confirm vial adequation for human use. 
▶ Single dose in an antecubital vein (target dose app. 185 MBq)
▶ In the GIGA CRC medical unit under the supervision of the principal investigator 
(ES), who will monitor adverse events.
▶ Classical acquisition method on an ECAT EXACT+ HR scanner (Siemens, Erlangen, 
Germany)
▶ Image acquisitions will start 85 minutes after injection, and 4 frames of 5 minutes 
will be obtained. 
▶ Images will be reconstructed using filtered back-projection algorithm including 
corrections for measured attenuation, dead time, random events, and scatter 
using standard software (Siemens ECAT - HR+ V7.1, Siemens/CTI, Knoxville, TN, USA)
3. Data acquisition : Amyloid -PET
▶ Wednesday or Thursday
▶ Team : 1 qualified + 1 “witness”
▶ 3T MRI at the CRC
▶ Multiparameter mapping (MPM) with longitudinal relaxation 
rate (R1), effective transverse relaxation rate (R2*), percent 
saturation because of magnetization transfer (MT), effective 
proton density (PD)
▶ Classical resting state functional MRI (360 volumes)
▶ Hippocampal sequence
3. Data acquisition : MRI
▶ Tuesday
▶ Team : 1 Neuropsychologist
▶ Modified PACC5 (computed sum z-scores):
- Free and Total Recall in the Free and Cued Selective Reminding Test (FCSRT)
- Delayed Recall in the Logical Memory Test (+ 7d)
- Delayed Recall in CVLT (+ 7d)
- Digit Symbol Substitution Test
- Verbal Fluency Test for animal category
- Mattis Dementia Rating Scale
▶ Memory for entities
▶ Stroop
▶ TMT
3. Data acquisition : Neuropsychological testing
▶ Tuesday PM
▶ Team : 1 MD + 1 Nurse
▶ In the GIGA CRC medical unit under the supervision of the principal 
investigator (ES), who will monitor adverse events.
▶ UCB-H®. Synthesized on site by Nucleis S.A. and the radiopharmacist
will confirm vial adequation for human use. 
▶ 20 seconds bolus into an accessible vein
▶ Mean injection will be 150 MBq. The effective total body dose is 
about 1.70E-02 mSv/MB
▶ 100 mins brain PET image acquisition plus 10 mins transmission
▶ Activity in the carotid artery as input function
3. Data acquisition : SV2A-PET (1/2)
▶ For 10 participations : Arterial blood input function
▶ Arterial cannula inserted (and removed) by a registered 
anesthetist 
▶ Arterial blood samples collected (1ml/sample ; max 15ml) during 
acquisition
▶ Determination of whole blood activity, plasma free fraction and 
level of [18F]UCB-H metabolites
3. Data acquisition : SV2A-PET (2/2)
▶ Tuesday PM
▶ Team : 1 investigator
▶ Saliva collection for ApoE testing
3. Data acquisition : Saliva sample
1. Scientific context
2. Questions, hypothesis, and experimental design 
3. Data acquisition & subjects
4. Data processing & inference




▶ PET average image will be created using all frames
▶ Averaged PET images will be manually reoriented and 
automatically co-registered to the structural magnetisation 
transfer map in individual space
▶ Co-registered PET image will be spatially normalized
▶ FLUT-PET : SUVR will be calculated using the whole cerebellum 
as reference region
▶ SV2A-PET : Regional brain activity will be obtained with a 
Logan method 
▶ SPM12 will be used for multiple regression analyses
4. Data processing
4. Data processing
▶ Multiple regression analyses
- Continuous variable : Clinial variables, PET data and anxiety
- Covariate : Age, sex, education, ApoE status
▶ Correlation with synaptic density (SV2A PET) :
- Severity of SCD
- Awareness of cognitive decline
- Neuropsychological assessments
▶ Influence of MRI measures on these correlations
4. Data processing
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▶ Negative correlation between the severity of subjective 
memory complaints and synaptic activity
▶ Positive correlation between memory test results 
(within the range of normality) and synaptic activity in 
the MTL. 
▶ Possible influence of MRI measures on the previous 
relationship, looking for mediation of remote 
connectivity in the default mode network
▶ Prediction of cognitive (short-term) evolution based of 
imaging biomarkers
5. Expected results and interpretation
▶ We expect to bring further characterization 
and understanding of SCD subjects and to 
better predict pejorative cognitive evolution.
5. Expected results and interpretation
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In the team who is in charge of
▶ Subject recruitment and planning : FM
▶ data acquisition : FM, ES, SL, EL, CH, AL, MB/AP, CB
▶ raw data storage (mass-storage?) and organisation ( BIDS?)
▶ scripting and batching for analysis : FM, MB, CP, CB
▶ results checking and reproducibility : SL, CB
▶ discussion and interpretation : FM, ES, CB
▶ manuscript writing : FM, ES
▶ making data open and data sharing : to be discussed
FM : François Meyer ; ES : Eric Salmon ; SL : Sophie Laloux ; EL : Erik Lambot ; CH :  Catherine Hagelstein ; AL  : Alexia Lesoinne ;
MB : Mohammed Bahri ; CP : Christope Phillips; CB: Cristine Bastin; AP: Alain Plenevaux
6. Project management
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7. Project administration : Ethical committee
7. Project administration : Insurance
▶ GMP production of radioligand from GE Healthcare and 
Nucleis S.A.
▶ F.R. - F.N.R.S 
▶ Fondation Léon Fredericq : Crédit Forfaitaire, Prix de l’Espoir
7. Project administration : Funding source
Thank you for your attention!
